MMEDF News and Press, Mind Medicine From 01/25/21

Mushroom & Psychedelic Stocks Are Hot In 2021 While many traders are looking for the next batch of green energy penny stocks to buy, others have found potential elsewhere. In fact, something huge happened this month that could make psychedelic and mushroom stocks more mainstream. ...

Palm Beach, FL – January 21, 2021 – Most of the news on advances for Covid-19 tend to focus on vaccines, however treatments are just as important. While vaccines can stop people from contracting Covid and becoming seriously ill, treatments will still be needed for those who al...

4 Psychedelic Stocks For Your Watch List This Year Whether you’ve traded for decades or just opened an account, the market attracts you for a reason. That is usually related to making money & penny stocks have become a clear focus for traders this year. Not only that, but...

MindMed (MMEDF) starts an early stage trial to test the effects of combining psychedelic substance LSD and party drug MDMA in an effort to reduce the negative emotions and anxiety that are sometimes associated with LSD when used in therapy or clinical settings.MindMed aims to understandi...

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD PR Newswire BASEL, Switzerland , Jan. 20, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced today...

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience PR Newswire Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORK , Jan. 14, 2021 /PRNews...

FinancialBuzz.com News Commentary New York, NY (1/12/2021) — Psychedelics are slowly becoming more acceptable as a legitimate treatment option for various anxiety and depression related mental illnesses. Depression is one of the most common chronic neurological disorders in moder...

MindMed (OTCQB: MMEDF) (NEO: MMED) , a leading psychedelic medicine biotech company today announced an innovative randomized placebo-controlled study evaluating the effects of daytime and evening administration of low doses of LSD on cognitive performance, sleep quality, mood, neu...

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers PR Newswire MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitiv...

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand Canada NewsWire Bolsters Cash on Hand to CAD $183.0m (USD $144.4m ) NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...